Dosis Announces Nationwide Precision Dosing Implementation with DaVita

Rhea-AI Summary

Dosis has rolled out its Smart Anemia Manager (SAM) at DaVita clinics nationwide, enhancing personalized dosing for erythropoiesis-stimulating agents (ESAs) used in treating chronic anemia in end-stage renal disease patients. This integration, which began in 2019, has influenced over 30 million dialysis treatments. CEO Shivrat Chhabra emphasized the importance of precision medicine in value-based care, aiming to improve patient outcomes while lowering healthcare costs through tailored dosing recommendations.

Positive

• Successful implementation of SAM at DaVita clinics, enhancing chronic disease management.
• Over 30 million dialysis treatments have benefited from personalized dosing recommendations.
• Shift towards precision medicine aligns with the trend of value-based care.

Negative

• None.

SAN FRANCISCO--(BUSINESS WIRE)-- Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the implementation of its flagship personalized dosing product at DaVita (NYSE: DVA) clinics nationwide. Dosis’s Smart Anemia Manager (SAM) personalizes drug dosing for erythropoiesis-stimulating agents (ESAs), a class of drugs used to treat end-stage renal disease patients with chronic anemia.

Integration of Dosis’s personalized dosing recommendations into DaVita’s anemia management protocols first began in 2019, and over 30 million dialysis treatments have been informed to date.

“We are incredibly excited about the impact of our technology on chronic disease management,” said Shivrat Chhabra, Chief Executive Officer and co-founder of Dosis. “The shift to value-based care is driving the need for precision medicine tools that maximize patient outcomes while reducing the cost of care. DaVita has been a visionary in realizing the potential of precision medicine in this exciting new era.”

Using each dialysis patient’s past ESA doses, hemoglobin levels, and target hemoglobin range, SAM calculates and delivers a personalized dosing recommendation for each patient that helps manage their hemoglobin levels while reducing unnecessary ESA exposure and drug cost. SAM’s personalized dosing recommendations are designed to improve upon conventional one-size-fits-all dosing approaches.

About Dosis Inc.

Dosis Inc. is a San Francisco-based precision medicine software company that was founded with the mission to transform chronic disease management by leveraging advancements in artificial intelligence and control algorithms. With a deep academic history, Dosis uses science, data, patient safety, and clinical evidence to create precision dosing tools. For more information about the technology behind SAM, visit dosisinc.com/platform, and for more information about Dosis, visit dosisinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005035/en/

Dosis Media Team

hello@dosisinc.com

353 Sacramento Street, Ste 1800

San Francisco, CA 94111

Source: Dosis Inc.

FAQ

What is the Smart Anemia Manager (SAM) by Dosis?

SAM is a personalized dosing product that tailors drug dosing for erythropoiesis-stimulating agents (ESAs) to manage chronic anemia in end-stage renal disease patients.

When was Dosis's SAM integrated into DaVita's protocols?

The integration of SAM into DaVita's anemia management protocols began in 2019.

How many dialysis treatments has SAM influenced?

SAM has informed over 30 million dialysis treatments to date.

What are the benefits of using SAM for dosing?

SAM aims to improve patient outcomes by providing personalized dosing recommendations, thereby reducing unnecessary ESA exposure and lowering drug costs.

What is the significance of precision medicine in Dosis's approach?

Precision medicine is crucial for maximizing patient outcomes and reducing the cost of care, aligning with the current shift to value-based care.